February 28, 2018 / 9:39 PM / 6 months ago

BRIEF-Allergan Says FDA Has Extended Ulipristal Acetate NDA Review Period To August 2018

Feb 28 (Reuters) - Allergan Plc:

* ALLERGAN ANNOUNCES FDA HAS EXTENDED THE ULIPRISTAL ACETATE NDA REVIEW PERIOD TO AUGUST 2018

* ALLERGAN PLC - PDUFA TARGET ACTION DATE HAS BEEN EXTENDED TO AUGUST 2018 TO PROVIDE TIME FOR A FULL REVIEW OF FILE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below